Managing motor complications remains one of the greatest long-term challenges in neurodegenerative movement disorders, especially dyskinesia in Parkinson's disease. While levodopa remains the gold standard symptomatic therapy, long-term administration frequently leads to motor fluctuations and involuntary choreiform or dystonic movements. Consequently, identifying objective circulating biomarkers that identify patients vulnerable to these motor complications has become a top clinical priority. Mitochondrial quality control pathways, encompassing mitophagy and the mitochondrial unfolded protein response, have emerged as pivotal biological processes underlying dopaminergic vulnerability. However, their precise relationship with peripheral clinical manifestations has remained elusive until recently.

Pathophysiological Hallmarks of Dyskinesia in Parkinson's Disease

Levodopa therapy effectively restores striatal dopamine levels, but chronic intermittent stimulation of sensitized postsynaptic receptors produces profound cellular adaptations. As Parkinson's disease progresses, the loss of presynaptic buffering mechanisms forces remaining dopaminergic terminals to endure erratic neurochemical surges. Therefore, downstream signaling pathways within the striatum undergo aberrant transcriptional and metabolic reprogramming. Recent research highlights how cellular organelle integrity, especially mitochondrial homeostasis, plays an active role in driving this maladaptive synaptic plasticity. When striatal neurons experience relentless metabolic stress, mitochondrial dysfunction triggers cascade responses that damage neuronal communication. Furthermore, clinicians often struggle to distinguish between isolated motor fluctuations, such as wearing-off phenomena, and peak-dose dyskinesias during early evolution. Because current assessments rely heavily on subjective patient diaries and clinical motor scales, objective circulating biomarkers represent an urgent unmet need. Establishing systemic indicators of mitochondrial pathway failure provides an accessible window into subclinical neurodegenerative stress. Ultimately, linking peripheral molecular profiles to specific motor complications will enable earlier therapeutic adjustments and protect patients from debilitating motor instability.

Mitochondrial Quality Control and the Mitophagy Cascade

Mitochondrial quality control constitutes a coordinated cellular defense network designed to eliminate defective organelles and resolve proteotoxic insults. Within this network, mitophagy serves as the selective autophagic clearance pathway mediated predominantly by the PTEN-induced kinase 1 and the E3 ubiquitin ligase Parkin. Under physiological conditions, healthy mitochondria continuously import and degrade PINK1. However, when mitochondrial membrane potential collapses, PINK1 accumulates on the outer mitochondrial membrane. Consequently, it recruits and phosphorylates Parkin to initiate polyubiquitination of damaged organellar targets. In addition to selective mitophagy, cells activate the mitochondrial unfolded protein response, an integrated transcriptional axis driven by activating transcription factor 5, activating transcription factor 4, and CHOP. This stress-response pathway upregulates protective chaperones and proteases to restore mitochondrial protein folding. When proteotoxic or bioenergetic stress exceeds compensatory thresholds, persistent pathway signaling reflects cellular breakdown. Emerging clinical evidence reveals that alterations in these cellular preservation systems are detectable not only within the central nervous system but also in peripheral circulation, reflecting systemic mitochondrial vulnerability.

Investigating Plasma Mitophagy and Mitochondrial Stress Markers

To clarify whether peripheral mitochondrial markers mirror motor complication subtypes, investigators conducted a comprehensive cross-sectional study enrolling 247 patients with Parkinson's disease. The research team systematically organized the cohort into three analytical cohorts: a mitophagy discovery set comprising 174 participants, a mitochondrial unfolded protein response discovery set with 179 participants, and an overlap subset of 106 patients with complete profiling across all assays. Using robust enzyme-linked immunosorbent assays, clinicians quantified plasma levels of key regulators, including PINK1, Parkin, PGAM5, ATF4, ATF5, and CHOP. Participants were categorized into patients exhibiting motor complications or those without motor complications, with further granular subtyping separating isolated wearing-off from dyskinesia. The investigators implemented rigorous multivariable logistic regression and least absolute shrinkage and selection operator regression models to control for confounding clinical covariates, including disease duration and levodopa equivalent daily doses. Furthermore, bootstrap resampling validated model stability across multiple testing iterations, ensuring that identified associations represented true biological divergence rather than analytical artifacts.

Dyskinesia in Parkinson's Disease: Key Findings from the Discovery Cohorts

Interestingly, overall mitophagy and mitochondrial unfolded protein response markers failed to distinguish general motor complications from non-complicated Parkinson's disease when evaluated broadly. However, granular subtyping revealed profound biochemical divergence specifically tied to dyskinesia in Parkinson's disease. Following rigorous batch correction and covariate adjustment, elevated plasma levels of the PINK1/Parkin ratio and ATF5 demonstrated statistically significant, independent associations with prevalent dyskinesia. Specifically, every unit increase in the PINK1/Parkin ratio doubled the likelihood of dyskinesia, yielding an adjusted odds ratio of 2.06. Similarly, elevated circulating ATF5 concentrations conferred an odds ratio of 2.27, reflecting substantial activation of the mitochondrial unfolded protein response. Most importantly, an integrated three-biomarker panel comprising PINK1, the PINK1/Parkin ratio, and ATF5 achieved an area under the receiver operating characteristic curve of 0.82 within the overlap subset. Notably, biomarker distributions exhibited a non-linear gradient across phenotypic subsets, progressively declining from isolated dyskinesia to combined dyskinesia with wearing-off, and reaching lowest levels in pure wearing-off presentations.

Translational Relevance and Clinical Decision-Making

These molecular findings provide practical clinical value for neurologists and movement disorder specialists managing Parkinson's disease. Because levodopa-induced involuntary movements significantly compromise functional independence and overall quality of life, preemptive risk stratification is paramount. Detecting an abnormal PINK1/Parkin ratio alongside elevated ATF5 could soon alert clinicians to underlying vulnerability before overt dyskinesias manifest during routine examination. Therefore, physicians could optimize pharmacotherapy proactively, choosing strategies that minimize peak-dose pulsatile dopamine delivery. Such interventions include utilizing continuous dopamine receptor agonists, monoamine oxidase-B inhibitors, or initiating catechol-O-methyltransferase inhibitors with tighter fractionated dosing. Additionally, these circulating biomarkers offer objective monitoring tools during clinical trials evaluating disease-modifying agents or neuroprotective compounds aimed at mitochondrial rescue. Integrating convenient peripheral blood draws into standard neurological evaluations bypasses the need for invasive cerebrospinal fluid sampling. Consequently, this accessible molecular approach brings personalized movement disorder management closer to routine bedside implementation, ensuring timely therapeutic adjustments before disabling complications permanently disrupt daily motor activities.

Future Perspectives on Mitochondrial Targeted Therapies

The clear association between systemic mitochondrial quality control markers and dyskinesia opens exciting avenues for therapeutic innovation. Historically, dyskinesia management relied primarily on symptomatic pharmacological adjustments or surgical options like deep brain stimulation. However, establishing mitochondrial unfolded protein response activation as an accomplice in dyskinesia pathophysiology suggests that restoring organelle resilience may alter clinical trajectories. Future clinical trials must investigate whether small molecules enhancing Parkin recruitment or modulating integrated stress signaling can suppress the cellular cascades driving dyskinesia in Parkinson's disease. Furthermore, longitudinal prospective cohorts are essential to confirm whether plasma elevations precede motor complication onset or merely mirror established tissue stress. Standardizing commercial assay platforms, validating cutoff thresholds across diverse global populations, and establishing regional reference standards will accelerate real-world implementation. As our understanding of mitochondrial biology deepens, peripheral biomarkers will undoubtedly transition from exploratory investigative tools to essential instruments for precision neurotherapeutics.

Frequently Asked Questions

What is the clinical significance of the PINK1/Parkin ratio in Parkinson's disease?

The plasma PINK1/Parkin ratio reflects active mitophagy signaling and mitochondrial clearance efficiency. In clinical research, an elevated ratio independently associates with a higher likelihood of dyskinesia, suggesting that unbalanced mitochondrial degradation pathways correlate with heightened vulnerability to levodopa-induced complications.

How does activating ATF5 relate to mitochondrial stress responses?

Activating transcription factor 5 serves as a primary transcriptional mediator of the mammalian mitochondrial unfolded protein response. When cells accumulate misfolded mitochondrial proteins or endure bioenergetic failure, ATF5 translocates to upregulate compensatory chaperones, providing a peripheral footprint of systemic cellular stress.

Can clinicians routinely use plasma mitochondrial biomarkers today?

Currently, plasma tests measuring PINK1, Parkin, and ATF5 remain investigative tools utilized primarily in clinical research settings. While showing an area under the curve of 0.82, broad clinical implementation requires prospective longitudinal validation, commercial standardization, and defined therapeutic thresholds across diverse patient populations.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment when evaluating patient care strategies. Refer to the latest local and national guidelines for clinical practice.

References

1. Qian S et al. Plasma PINK1/Parkin ratio and ATF5 as potential biomarkers associated with dyskinesia in Parkinson's disease. Neurobiol Dis. 2026 Nov. doi: 10.1016/j.nbd.2026.107638. PMID: 42833593.
2. Espay AJ, Morgante F, Merola A, et al. Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol. 2018;84(6):797-811.
3. Harper JW, Ordureau A, Heo JM. Building and decoding ubiquitin chains for mitophagy. Nat Rev Mol Cell Biol. 2018;19(2):93-108.
4. Fiorese CJ, Schulz AM, Lin YF, et al. The transcription factor ATF5 mediates a mammalian mitochondrial UPR. Curr Biol. 2016;26(15):2037-2043.